Crosstalk between Long non coding RNAs, microRNAs and DNA damage repair in prostate cancer: new therapeutic opportunities?
Simple Summary Non-coding RNAs are a type of genetic material that doesn't make protein,
but performs diverse regulatory functions. In prostate cancer, most treatments target proteins …
but performs diverse regulatory functions. In prostate cancer, most treatments target proteins …
[HTML][HTML] Androgen Receptor–Interacting Proteins in Prostate Cancer Development and Therapy Resistance
Endocrine therapy for prostate cancer is based on the use of drugs that diminish androgen
concentration and androgen receptor (AR) signaling inhibitors and is limited by the …
concentration and androgen receptor (AR) signaling inhibitors and is limited by the …
MYC reshapes CTCF-mediated chromatin architecture in prostate cancer
Z Wei, S Wang, Y Xu, W Wang, F Soares… - Nature …, 2023 - nature.com
MYC is a well characterized oncogenic transcription factor in prostate cancer, and CTCF is
the main architectural protein of three-dimensional genome organization. However, the …
the main architectural protein of three-dimensional genome organization. However, the …
ST3 beta-galactoside alpha-2, 3-sialyltransferase 1 (ST3Gal1) synthesis of Siglec ligands mediates anti-tumour immunity in prostate cancer
Immune checkpoint blockade has yet to produce robust anti-cancer responses for prostate
cancer. Sialyltransferases have been shown across several solid tumours, including breast …
cancer. Sialyltransferases have been shown across several solid tumours, including breast …
Mechanism-centric regulatory network identifies NME2 and MYC programs as markers of Enzalutamide resistance in CRPC
S Panja, MI Truica, CY Yu, V Saggurthi… - Nature …, 2024 - nature.com
Heterogeneous response to Enzalutamide, a second-generation androgen receptor
signaling inhibitor, is a central problem in castration-resistant prostate cancer (CRPC) …
signaling inhibitor, is a central problem in castration-resistant prostate cancer (CRPC) …
SMARCB1 loss activates patient-specific distal oncogenic enhancers in malignant rhabdoid tumors
NQ Liu, I Paassen, L Custers, P Zeller… - Nature …, 2023 - nature.com
Malignant rhabdoid tumor (MRT) is a highly malignant and often lethal childhood cancer.
MRTs are genetically defined by bi-allelic inactivating mutations in SMARCB1, a member of …
MRTs are genetically defined by bi-allelic inactivating mutations in SMARCB1, a member of …
An atlas of accessible chromatin in advanced prostate cancer reveals the epigenetic evolution during tumor progression
Metastatic castration-resistant prostate cancer (mCRPC) is a lethal disease that resists
therapy targeting androgen signaling, the primary driver of prostate cancer. mCRPC resists …
therapy targeting androgen signaling, the primary driver of prostate cancer. mCRPC resists …
Tumor cell-based liquid biopsy using high-throughput microfluidic enrichment of entire leukapheresis product
Abstract Circulating Tumor Cells (CTCs) in blood encompass DNA, RNA, and protein
biomarkers, but clinical utility is limited by their rarity. To enable tumor epitope-agnostic …
biomarkers, but clinical utility is limited by their rarity. To enable tumor epitope-agnostic …
Development of sexual dimorphism of skeletal muscles through the adrenal cortex, caused by androgen-induced global gene suppression
The zona fasciculata (zF) in the adrenal cortex contributes to multiple physiological actions
through glucocorticoid synthesis. The size, proliferation, and glucocorticoid synthesis …
through glucocorticoid synthesis. The size, proliferation, and glucocorticoid synthesis …
Androgen receptor activity in prostate cancer dictates efficacy of bipolar androgen therapy through MYC
Testosterone is the canonical growth factor of prostate cancer but can paradoxically
suppress its growth when present at supraphysiological levels. We have previously …
suppress its growth when present at supraphysiological levels. We have previously …